Male Hypogonadism: The Partner and Family Role in Diagnosis, Treatment, and Recovery

The diagnosis is two early-morning tests, not one number

The Endocrine Society's 2018 guideline recommends making the diagnosis only in men who have symptoms and signs consistent with testosterone deficiency together with unequivocally and consistently low serum testosterone, measured fasting in the morning with an accurate assay and confirmed by repeating the measurement [1]. The American Urological Association guideline requires low total testosterone plus symptoms or signs, uses a total testosterone below 300 ng/dL as a reasonable cutoff, and says the diagnosis should follow two measurements taken early in the morning on separate occasions [2]. A single low value, or symptoms alone, are not enough [2].

Cut points differ between sources. The harmonized reference range built from 9,054 men in four cohort studies, cross-calibrated to a CDC reference method, puts the 2.5th to 97.5th percentile for healthy non-obese men aged 19 to 39 at 264 to 916 ng/dL, and much of the variation between cohorts came from assay differences [4]. The AUA cutoff of 300 ng/dL is a separate, guideline-based threshold [2].

Symptoms are the other half of the diagnosis, and a number alone misleads in both directions. In the Boston Area Community Health Survey of 1,475 men, 24% had a total testosterone below 300 ng/dL, yet among men 50 and older with low testosterone, 47.6% had no symptoms; the crude prevalence of symptomatic androgen deficiency was 5.6% and rose to 18.4% among 70-year-olds [6].

Once the deficiency is confirmed, further testing looks for the cause. If total testosterone is near the lower limit of normal or a condition alters sex hormone-binding globulin, the guideline recommends free testosterone by equilibrium dialysis or an accurate formula, and LH and FSH testing separates primary from secondary hypogonadism [1]. Per the Testim label, primary hypogonadism is testicular failure with gonadotropins above the normal range, and hypogonadotropic hypogonadism is a gonadotropin or LHRH deficiency or pituitary-hypothalamic injury with gonadotropins in the normal or low range [3].

Where a partner or family member can realistically help

Three roles fit what the guidelines and labels describe: helping make sure the repeat morning tests are scheduled and completed [1][2], joining the fertility discussion before treatment starts [1], and preventing gel transfer within the household [3].

The nearest research on family involvement is a systematic review of 30 studies in 22 cohorts of adults with arthritis, chronic cardiovascular disease, diabetes and end-stage renal disease. Family emphasis on self-reliance, family cohesion and attentive responses to symptoms were associated with better patient outcomes, while critical, overprotective, controlling or distracting responses were associated with worse ones; the authors suggest future interventions emphasize family support for the patient's autonomous motivation [5]. Those conditions are not hypogonadism, so this is a pattern from other illnesses, not a finding for this diagnosis.

One cause a household may notice is long-term opioid use. Among 54 men taking sustained-action oral opioids several times a day for nonmalignant pain, compared with 27 men taking none, total testosterone was subnormal in 74%, and 39 of 45 men (87%) who reported normal erectile function before starting opioids reported severe erectile dysfunction or diminished libido afterwards [7].

Three topics to settle before the first dose

Fertility

Testosterone therapy suppresses sperm production. The Endocrine Society recommends against starting testosterone in men who are planning fertility in the near term [1].

A literature review describes human chorionic gonadotropin and selective estrogen receptor modulators such as clomiphene citrate as therapies that protect the testis, notes that routine aromatase inhibitor use is not recommended for lack of long-term data, and reports that in studies of hormonal contraception most men had a return of normal sperm production within 1 year after discontinuation [8]. The regulatory status of those alternatives matters: clomiphene is FDA-approved only for ovulatory dysfunction in women, so male use is off-label [9]; enclomiphene is not FDA-approved in any form [10]; hCG is approved for selected cases of hypogonadotropic hypogonadism in males [11].

Health history that changes the decision

The Endocrine Society guideline recommends against starting testosterone therapy in men who have breast or prostate cancer, a palpable prostate nodule or induration, a PSA above 4 ng/mL (or above 3 ng/mL in men at increased risk of prostate cancer, such as African American men or men with a first-degree relative with prostate cancer, without further urological evaluation), elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, a heart attack or stroke within the previous 6 months, or thrombophilia [1]. The same guideline suggests against routinely prescribing testosterone to all men aged 65 and older and favors an individualized discussion of risks and benefits for those with symptoms and consistently low morning levels [1].

Sport

If he competes under anti-doping rules, the WADA 2026 Prohibited List names testosterone in S1.1 (prohibited at all times), chorionic gonadotrophin and LH in S2.2.1, clomifene in S4.2 and anastrozole in S4.1. A prescription does not make them allowed; a Therapeutic Use Exemption is needed [12].

If he uses a gel, the label warning includes the household

The Testim label carries a boxed warning on secondary exposure: virilization has been reported in children who were secondarily exposed to testosterone gel, and children should avoid contact with unwashed or unclothed application sites [3]. Reported signs include enlargement of the penis or clitoris, development of pubic hair, increased erections and libido, aggressive behavior and advanced bone age; in most cases these regressed when exposure was removed, but in a few the enlarged genitalia did not fully return to age-appropriate size and bone age stayed modestly greater than chronological age [3]. For adult women, the label lists changes in body hair distribution, a significant increase in acne and other signs of virilization, and says the gel should be promptly discontinued until the cause of virilization has been identified [3]. Testim is contraindicated in women who are pregnant [3].

The Testim label says to wash hands with soap and water after applying the gel, cover the application site with clothing after the gel has dried, and wash the site before anticipated skin-to-skin contact with another person. It also says not to apply the gel to the genitals or abdomen and that Testim is not substitutable with other topical testosterone products [3].

Boxed warnings are not the same across the class. Aveed's boxed warning covers serious pulmonary oil microembolism reactions and anaphylaxis, and the product is available only through a restricted program with 30 minutes of observation after each injection [13]. Depo-Testosterone and generic testosterone cypionate and enanthate injections have no boxed warning [14]. FDA removed language about increased cardiovascular risk from the boxed warning of all testosterone products in a class-wide labeling action dated 2/28/2025, and required a blood pressure warning where a product lacked one [15].

What gets tracked during treatment

The Endocrine Society recommends aiming for mid-normal testosterone concentrations with any approved formulation and, during the first year, evaluating symptoms, adverse effects and compliance, measuring serum testosterone and hematocrit, and evaluating prostate cancer risk [1]. The Testim label adds its own hematocrit schedule: check before starting, re-evaluate 3 to 6 months after starting, then annually; if hematocrit becomes elevated, the label says to stop therapy until it decreases to an acceptable concentration [3].

Blood pressure belongs on the same list. In a 16-week ambulatory monitoring study on the Testim label, mean systolic and diastolic pressure rose 2.7 and 1.1 mm Hg from baseline [3]. The label says to monitor blood pressure periodically, especially in men with hypertension, and does not recommend the product in uncontrolled hypertension [3].

On heart safety, TRAVERSE randomized 5,246 men aged 45 to 80 with hypogonadism symptoms, two fasting testosterone levels below 300 ng/dL, and existing or high risk of cardiovascular disease to 1.62% transdermal gel or placebo [16]. A first major cardiovascular event occurred in 7.0% on testosterone gel and 7.3% on placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17), while atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and venous thromboembolism (1.7% vs 1.2%) were numerically more common with testosterone [3]. That result is for a gel in this population, not proof that every product and dose is safe [16].

FDA states that approved testosterone products are for men with low testosterone plus an associated medical condition, and that none is approved for low testosterone without one [17]. The current Testim and Depo-Testosterone labels still state that safety and efficacy in age-related, or late-onset, hypogonadism have not been established, and FDA requested in June 2026 that this limitation of use be removed [17][3][14].